STOCK TITAN

Rhythm Pharmaceuticals Inc. - RYTM STOCK NEWS

Welcome to our dedicated news page for Rhythm Pharmaceuticals (Ticker: RYTM), a resource for investors and traders seeking the latest updates and insights on Rhythm Pharmaceuticals.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Rhythm Pharmaceuticals's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Rhythm Pharmaceuticals's position in the market.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.72%
Tags
none
-
Rhea-AI Summary
Rhythm Pharmaceuticals grants inducement equity grants to new employees
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary
Rhythm Pharmaceuticals reports Q2 2023 net revenue of $19.2 million from global sales of IMCIVREE. Strong U.S. commercial progress with over 125 new prescriptions for Bardet-Biedl syndrome (BBS) in Q2 2023. Achieves commercial sales milestone and eligible for $25 million investment. Plans to submit IND for RM-718 by end of 2023. Phase 3 trial for setmelanotide in hypothalamic obesity to be fully enrolled by end of 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
27.52%
Tags
Rhea-AI Summary
Rhythm Pharmaceuticals, Inc. announced the results of The CAREgiver Burden in BBS (CARE-BBS) study, which highlight the multifaceted burden of hyperphagia and obesity for adult caregivers, families, and patients living with Bardet-Biedl Syndrome (BBS). The study found that hyperphagia negatively affects performance in school, work, and social relationships. The research was published in The Orphanet Journal of Rare Diseases.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.23%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.34%
Tags
conferences earnings
-
Rhea-AI Summary
Rhythm Pharmaceuticals, Inc. has granted inducement equity grants to six new employees. The grants consist of 25,970 stock options and 12,985 restricted stock units (RSUs). The stock options have an exercise price of $16.26 per share and will vest over a three-year period. The RSUs will vest over four years. These grants are subject to the terms of the Inducement Plan adopted by Rhythm's board of directors.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.75%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.4%
Tags
conferences
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.4%
Tags
none
Rhea-AI Summary
Rhythm Pharmaceuticals has announced a collaboration with Genpharm Services to commercialize IMCIVREE in Gulf Cooperation Council (GCC) countries. IMCIVREE is approved for the treatment of hyperphagia and obesity due to Bardet-Biedl syndrome (BBS) or genetically-confirmed biallelic pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1 (PCSK1), or leptin receptor (LEPR) deficiency. This exclusive agreement allows physicians in Saudi Arabia, United Arab Emirates, Kuwait, Qatar, Oman, and Bahrain to prescribe IMCIVREE to qualifying patients. Rhythm estimates that there are over 800 people living with BBS in GCC countries and approximately 100 people living with Biallelic POMC, PCSK1, or LEPR deficiency.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.79%
Tags
none
Rhythm Pharmaceuticals Inc.

Nasdaq:RYTM

RYTM Rankings

RYTM Stock Data

2.43B
44.99M
0.52%
112.26%
16.19%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
US
Boston

About RYTM

rhythm pharmaceuticals inc. is a biotechnology company located in 855 boylston street, 11th floor, boston, ma, united states.